Market Overview:
The recombinant DNA technology market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of this market is mainly attributed to the increasing demand for recombinant DNA products in the biotechnology and pharmaceutical industries, and rising investments in R&D by academic and government research institutes. However, stringent regulatory norms may restrain the growth of this market during the forecast period. On the basis of type, the recombinant DNA technology market can be segmented into therapeutic agents, vaccines, biotech crops, and specialty chemicals. The therapeutic agents segment is expected to account for the largest share of this market in 2018 owing to its growing demand for monoclonal antibodies (mAbs) and other therapeutics products worldwide. By application, this market can be divided into biotechnology and pharmaceutical companies; academic & government research institutes; contract research organizations (CROs); food & agriculture companies; environmental testing laboratories; diagnostic centers; blood banks & tissue banks; hospitals & clinics; veterinary clinics & farms ;and others).
Product Definition:
Recombinant DNA technology is the process of artificially combining genetic material from different sources. This technique is important because it can be used to create new genes or modify existing ones. This can be used to produce proteins that are not found in nature, or to create organisms that have been modified for medical purposes or industrial applications.
Therapeutic Agent:
Therapeutic agent is a chemical or drug used for the treatment of disease. It can be used by itself or in combination with other drugs.
1) Local acting agents, and 2) Systemic acting agents. The local acting therapeutic agent usually has an action at the site of disease while systemic acting therapeuticagents have an effect throughout body.
Vaccine:
A vaccine is a protection against diseases. It works by stimulating the body's immune system to produce antibodies against the disease-causing microorganism. The most common types of vaccines are those for polio, rotavirus, smallpox, and hepatitis B.
Polio vaccine was first developed in this technology.
Application Insights:
The biotechnology and pharmaceutical companies segment dominated the global market in terms of revenue share in 2017. This is owing to the rising demand for drugs with a high therapeutic index such as recombinant erythropoietin, interferon, monoclonal antibody, growth hormone and insulin. The academic and government research institutes accounted for a significant share of the overall revenue due to increasing R&D activities pertaining to advanced bio-tech products that can revolutionize healthcare delivery systems across various applications such as therapeutics & vaccines, diagnostics & labelling, stem cells management & banking among others.
Regional Analysis:
North America accounted for the largest revenue share in 2017. The presence of a large number of biopharmaceutical companies and strong government support are some factors driving the market growth in this region. For instance, National Institute of Health (NIH) provides funding to universities and other research organizations for developing novel therapies using recombinant DNA techniques. In addition, approval and commercialization of products based on rDNA technology is boosting the regional market growth.
For instance, ZIKV vaccine developed by NewLink Genetics received emergency use authorization from FDA in December 2016; however, it was not commercially available until February 2017 due to manufacturing issues faced by its manufacturer Pfizer Inc. However, Asia Pacific is expected to be fastest growing region during the forecast period owing to increasing focus on new product development with a major emphasis on vaccines against emerging infectious diseases such as Zika virus disease & Ebola virus disease among others that require urgent attention from governments worldwide.
Growth Factors:
- Increasing demand for recombinant DNA technology in the field of biotechnology and pharmaceuticals for the production of therapeutic proteins and enzymes.
- Growing application of recombinant DNA technology in research activities for gene cloning, sequencing, and expression studies.
- Rising demand from emerging economies for recombinant DNA technology products owing to the increasing adoption of advanced technologies in these regions.
- Technological advancements that have led to the development of novel methods and instruments for recombinant DNA technology-based applications such as CRISPR/Cas9 genome editing system .
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant DNA Technology Market Research Report
By Type
Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals
By Application
Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, Others
By Companies
Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript, Pfizer Inc., Novo Nordisk, Sanofi, Merck KGaA, Profacgen, Biocon, GlaxoSmithKline, Cibus, Horizon Discovery Group, New England Biolabs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant DNA Technology Market Report Segments:
The global Recombinant DNA Technology market is segmented on the basis of:
Types
Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Monsanto Company
- Roche
- Biogen
- Amgen
- Novartis
- Eli Lilly and Company
- GenScript
- Pfizer Inc.
- Novo Nordisk
- Sanofi
- Merck KGaA
- Profacgen
- Biocon
- GlaxoSmithKline
- Cibus
- Horizon Discovery Group
- New England Biolabs
Highlights of The Recombinant DNA Technology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Therapeutic Agent
- Vaccine
- Biotech Crops
- Specialty Chemicals
- By Application:
- Biotechnology and Pharmaceutical Companies
- Academic & Government Research Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant DNA Technology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant DNA technology is a process that allows scientists to create new forms of genetic material by combining pieces of DNA from different sources. This technology has been used to create vaccines, gene therapies, and other medical treatments.
Some of the major companies in the recombinant dna technology market are Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript, Pfizer Inc., Novo Nordisk, Sanofi, Merck KGaA, Profacgen, Biocon, GlaxoSmithKline, Cibus, Horizon Discovery Group, New England Biolabs.
The recombinant dna technology market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant DNA Technology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant DNA Technology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant DNA Technology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant DNA Technology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant DNA Technology Market Size & Forecast, 2018-2028
4.5.1 Recombinant DNA Technology Market Size and Y-o-Y Growth
4.5.2 Recombinant DNA Technology Market Absolute $ Opportunity
Chapter 5 Global Recombinant DNA Technology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant DNA Technology Market Size Forecast by Type
5.2.1 Therapeutic Agent
5.2.2 Vaccine
5.2.3 Biotech Crops
5.2.4 Specialty Chemicals
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant DNA Technology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant DNA Technology Market Size Forecast by Applications
6.2.1 Biotechnology and Pharmaceutical Companies
6.2.2 Academic & Government Research Institutes
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant DNA Technology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant DNA Technology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant DNA Technology Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant DNA Technology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant DNA Technology Market Size Forecast by Type
9.6.1 Therapeutic Agent
9.6.2 Vaccine
9.6.3 Biotech Crops
9.6.4 Specialty Chemicals
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant DNA Technology Market Size Forecast by Applications
9.10.1 Biotechnology and Pharmaceutical Companies
9.10.2 Academic & Government Research Institutes
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant DNA Technology Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant DNA Technology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant DNA Technology Market Size Forecast by Type
10.6.1 Therapeutic Agent
10.6.2 Vaccine
10.6.3 Biotech Crops
10.6.4 Specialty Chemicals
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant DNA Technology Market Size Forecast by Applications
10.10.1 Biotechnology and Pharmaceutical Companies
10.10.2 Academic & Government Research Institutes
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant DNA Technology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant DNA Technology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant DNA Technology Market Size Forecast by Type
11.6.1 Therapeutic Agent
11.6.2 Vaccine
11.6.3 Biotech Crops
11.6.4 Specialty Chemicals
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant DNA Technology Market Size Forecast by Applications
11.10.1 Biotechnology and Pharmaceutical Companies
11.10.2 Academic & Government Research Institutes
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant DNA Technology Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant DNA Technology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant DNA Technology Market Size Forecast by Type
12.6.1 Therapeutic Agent
12.6.2 Vaccine
12.6.3 Biotech Crops
12.6.4 Specialty Chemicals
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant DNA Technology Market Size Forecast by Applications
12.10.1 Biotechnology and Pharmaceutical Companies
12.10.2 Academic & Government Research Institutes
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant DNA Technology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant DNA Technology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant DNA Technology Market Size Forecast by Type
13.6.1 Therapeutic Agent
13.6.2 Vaccine
13.6.3 Biotech Crops
13.6.4 Specialty Chemicals
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant DNA Technology Market Size Forecast by Applications
13.10.1 Biotechnology and Pharmaceutical Companies
13.10.2 Academic & Government Research Institutes
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant DNA Technology Market: Competitive Dashboard
14.2 Global Recombinant DNA Technology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Monsanto Company
14.3.2 Roche
14.3.3 Biogen
14.3.4 Amgen
14.3.5 Novartis
14.3.6 Eli Lilly and Company
14.3.7 GenScript
14.3.8 Pfizer Inc.
14.3.9 Novo Nordisk
14.3.10 Sanofi
14.3.11 Merck KGaA
14.3.12 Profacgen
14.3.13 Biocon
14.3.14 GlaxoSmithKline
14.3.15 Cibus
14.3.16 Horizon Discovery Group
14.3.17 New England Biolabs
